Project Grant R21AI187942
Award Date
7/7/25
Completion Date
6/30/27
Dollars Obligated
$421K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $200,016 to The Regents of the University of California, San Francisco (UCSF) to develop a non-viral genome editing therapy for Artemis-deficient severe combined immunodeficiency (ART-SCID). The 5-year project aims to establish expertise in non-viral CRISPR/Cas9 editing of human hematopoietic stem cells, preclinical...
This Project Grant award of $405,497.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop a compact viral system for robust, concurrent CRISPR activation and interference (CRISPRa/i) in primary murine immune cells. The goal is to use this system to map the gene regulatory network controlling BCL11B activation and T cell lineage commitment. Key innovations include CRISPR RNA-scaffolds to recruit...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $657,673 to the Regents of the University of Minnesota to conduct research on non-deletional CD8+ T cell tolerance. The research aims to define the gene regulation that inhibits self-reactive CD8+ T cells and classify different types of self-reactive CD8+ T cell clones, in order to understand which tolerance...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $437,250 to the Regents of the University of Minnesota to conduct research on using extracellular vesicle-associated adeno-associated virus (EV-AAV) vectors for gene therapy targeting the airway epithelium in non-human primates. The goal is to achieve efficient and widespread transgene expression, particularly in the airway basal stem cells, to...
This $907,800 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a universal bacterial genome editing platform based on phage recombinases. The University of Rochester is leading this research to create a broadly-functioning recombineering system that can edit the genomes of diverse bacterial species, including clinically-relevant pathogens. Key aspects...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) provides $247,236 to the Regents of the University of Minnesota to investigate the expansion and function of long-lived effector CD8 T cells in the mature memory compartment. The research aims to determine the proinflammatory cytokines that support the formation and persistence of this T cell population, as well as how...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,483,910 to The Washington University in St. Louis to conduct research on novel genetic mechanisms underlying primary immune regulation disorders. The 5-year project, which commenced on April 8, 2025, aims to investigate three key areas: 1) epigenetic mechanisms leading to autosomal random monoallelic expression in...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $783,191.00 to the Regents of the University of Minnesota to conduct in vivo gene therapy research for Fanconi anemia. The award period runs from September 1, 2025 to August 31, 2028. As a prominent land-grant research institution, the University of Minnesota leverages its extensive academic capabilities to support the program's objectives of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $919,501 to Emmune Inc. to develop a non-viral gene therapy platform for delivering the ECD4-IG therapeutic protein as a practical approach for lifelong suppression of HIV replication. The goal is to establish a 'functional cure' for HIV through a single intramuscular injection that can sustain...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $658,426 to The Children's Hospital of Philadelphia (CHOP) to conduct research on chronic STAT3 signaling and its impact on CD8 T cell dysfunction. The key objectives are to investigate the role of the CD39/adenosine axis in impairing CD8 T cell function in the context of STAT3 gain-of-function (GOF) disease, and to...